Evoke Pharma Inc. (EVOK)

[DrGoodwrench]

The bigger market for this drug is for off label use as an anti-emetic for postoperative patients having nausea and/or vomiting. The 2021 Medicare PQRS measures will include reducing outpatient admits for nausea and vomiting and the only currently available non intravenous or oral medications to treat patients at home after surgery are Compazine suppositories ( serious side reactions and people hate suppositories), or very expensive Zofran ODT ( oral dissolving tablets) that when you are already nauseated are not a great solution. The Intranasal route of Metoclopramide will be the most readily tolerated and should also be the most effective as loss of GI motility from general Anesthesia and from Narcotic pain medications is the primary cause of nausea and vomiting in the first few days post-op. This HUGE market will be driven by physicians looking for a means to ensure they capture the 10% Medicare hold back of PQRS.